Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021

Diana Mendesa Health & Value, Pfizer Ltd, Tadworth, UK

https://orcid.org/0000-0002-1672-4906

Ruth Chapmanb Evidence Synthesis, Modeling and Communication, Evidera, London, UK

Peter Galc Evidence Synthesis, Modeling and Communication, Evidera, Budapest, Hungary

Jessica Atwelld Medical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc, Collegeville, PA, USA

Jennifer L. Nguyend Medical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc, Collegeville, PA, USA

Libby Hamsona Health & Value, Pfizer Ltd, Tadworth, UK

Manuela Di Fuscoe Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA

https://orcid.org/0000-0003-0079-7331

Carole Czudekf Vaccines Medical Affairs, Pfizer Ltd, Tadworth, UK

Jingyan Yange Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA;g Institute for Social and Economic Research and Policy, Graduate School of Arts and Science, Columbia University, New York, NY, USACorrespondence[email protected]

https://orcid.org/0000-0001-5523-649X

show all

Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date